Soleo Health Expanding Ultra-rare Drug Distribution Products Portfolio

Soleo Health, an innovative leader and national provider of complex specialty pharmacy and infusion services, recently joined the treatment center directory for GIVLAARI^® (givosiran), managed by Alnylam Pharmaceuticals. This inclusion allows Soleo Health to administer GIVLAARI in adults with Acute Hepatic Porphyria (AHP).

Soleo Health operates 20 locations throughout the U.S. with national nursing coverage and pharmacy licensure in 50 states and is accredited by The Joint Commission.

GIVLAARI is the first FDA-approved treatment for AHP in adults. AHP refers to a family of ultra-rare genetic disorders that results in the buildup of neurotoxins, which form due to a defect in the production of heme, a component of hemoglobin. GIVLAARI is a once-monthly injection for subcutaneous use, which reduces the levels of neurotoxins associated with AHP attacks and other AHP disease manifestations in adults.

Soleo Health offers GIVLAARI injections for subcutaneous use in patients’ homes or at one of its ambulatory infusion centers, supported and administered by its experienced staff, trained on the clinical profile and delivery of GIVLAARI. Soleo Health also dispenses Alnylam Pharmaceuticals’ commercial RNAi therapeutic product ONPATTRO^® (patisiran),

Soleo Health also was recently selected as a preferred provider by Cigna’s eviCore healthcare to participate in its specialty pharmacy network. eviCore serves as the network manager overseeing Cigna’s ancillary service offering of specialty pharmacy and infusion services across its nationwide system, which serves more than 14 million lives.

Effective February 1, 2021, Soleo Health provides a range of specialty and non-specialty infusion services to Cigna members through eviCore, including anti-infectives, bleeding disorders, inotropic, immunoglobulin (IV and subcutaneous), parenteral nutrition and specialty biologics therapies.

Takeaway: Soleo Health is expanding its portfolio of infusible and injectable specialty pharmaceuticals to elevate the company’s levels of quality patient care and therapeutic service offerings